Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. Long-acting cabotegravir + rilpivirine as maintenance therapy: ATLAS week 48 results. CROI 2019, abstract 139.
DNA-pas belooft minder bijwerkingen, betere patiëntenzorg en lagere kosten
apr 2023